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There are significant differences in the progress and approaches to drug development 
for visceral leishmaniasis (VL) and cutaneous leishmaniasis (CL).  VL, caused by L. 
donovani and L. infantum, is potentially fatal and is the primary focus for drug R & D. 
The need for new drugs is urgent as the standard pentavalent antimonials are now 
almost obsolete in the key endemic area in Bihar state, India due to resistance.  A 
number of amphotericin B lipid formulations have proved effective in the treatment VL, 
although only the liposomal formulation, AmBisome®, has become a standard treatment 
and demonstrated efficacy in single dose treatment and in combination therapy.  Major 
challenges remain for VL treatment due to regional differences in response rates, and 
co-infections with HIV.  Despite extensive screening and evaluation projects, few safe, 
oral, short course, cheap drugs are close to clinical development.  
There are limited treatment options for CL. One problem is the variation in drug 
effectiveness across the different Leishmania species that cause CL. Two recent 
Cochrane analyses of clinical trials of CL emphasized that most clinical studies did not 
meet standards of randomized placebo controlled trials. One promising approach has 
been the development of topical formulations, so far most successful for paromomycin.  
Another approach to CL treatment is to accelerate self-cure through the use of 
immunomodulators as adjunct therapies, for example, imiquimod.  
All attempts to discover and develop novel drugs for neglected infectious diseases 
depend on a network of partnerships, upon involvement of PDPs and the pharmaceutical 
industry and the involvement of key players in disease endemic countries. The issues of 
changing patterns of funding and involvement of different sectors all play a part in 
bringing new treatments to patients.  
 
